Gastric Cancer Stage
11
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer
Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China
Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer
Stomach Cancer Exosome-based Detection
Complete Mesogastric Excision With D2 Lympadenectomy for Gastric Cancer:
Association Between Multiple Coagulation-related Factors and Lymph Node Metastasis in Patients With Gastric Cancer: A Retrospective Cohort Study
A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
Study of CT and MR in the Gastric Cancer
Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer